Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

A class claims in a federal complaint that Akorn Inc.’s executives did not disclose that the pharmaceutical company’s noncompliance with federal data integrity requirements would jeopardize its acquisition by a health care firm, causing share prices to drop 38 percent to $18.65.

CHICAGO – A class claims in a federal complaint that Akorn Inc.’s executives did not disclose that the pharmaceutical company’s noncompliance with federal data integrity requirements would jeopardize its acquisition by a health care firm, causing share prices to drop 38 percent to $18.65.

Categories / Business, Financial, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...